Want to see IN:ABBOTINDIA full AI Analyst Report?
Top Page
Abbott India Limited
(ABBOTINDIA)
Select Model
Select Model
Rating:73Outperform
Price Target:
₹30,191.00
▲(15.52% Upside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by strong financial performance (solid growth, high profitability, very low leverage, and strong cash conversion). This is tempered by a mixed technical picture (near-term softness with neutral momentum) and a relatively high valuation (P/E ~37), only partly offset by the dividend yield.
Positive Factors
Steady Revenue Growth
The multi-year revenue increase indicates sustained demand for Abbott India’s branded medicines and healthcare products, supported by its broad therapy portfolio and established distribution and prescription-led channel presence.
Negative Factors
Gross Margin Compression
The sharp margin decline may reflect an unfavorable product mix, higher input costs or pricing pressure. If persistent, it could reduce the quality and durability of earnings despite strong reported net profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
The multi-year revenue increase indicates sustained demand for Abbott India’s branded medicines and healthcare products, supported by its broad therapy portfolio and established distribution and prescription-led channel presence.
Read all positive factors
Abbott India Limited (ABBOTINDIA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹543.69B
Dividend Yield2.05%
Average Volume (3M)2.44K
Price to Earnings (P/E)33.6
Beta (1Y)0.41
Revenue Growth6.29%
EPS Growth11.18%
CountryIN
Employees3,749
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)730.37
Shares Outstanding21,249,302
10 Day Avg. Volume553
30 Day Avg. Volume2,444
Financial Highlights & Ratios
PEG Ratio3.65
Price to Book (P/B)11.53
Price to Sales (P/S)7.95
P/FCF Ratio33.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)817.22
Revenue Forecast (FY)₹75.29B
Abbott India Limited Business Overview & Revenue Model
Company Description
Abbott India Limited is a pharmaceutical enterprise that conducts its operations across India. The company provides an extensive portfolio of medicinal products designed for a broad spectrum of therapeutic areas, including women's health, digestiv...
How the Company Makes Money
Abbott India Limited primarily makes money by selling pharmaceutical and healthcare products in India, with revenue largely recognized from the sale of finished formulations (branded medicines and related healthcare products) to trade channels (e....
Abbott India Limited Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
88
Very Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 69.29B | 64.07B | 58.47B | 53.47B | 49.10B |
| Gross Profit | 25.10B | 28.96B | 26.15B | 23.63B | 22.43B |
| EBITDA | 21.74B | 19.70B | 17.01B | 13.60B | 11.65B |
| Net Income | 15.52B | 14.14B | 12.01B | 9.49B | 7.99B |
Balance Sheet | |||||
| Total Assets | 65.02B | 59.17B | 51.93B | 45.56B | 42.24B |
| Cash, Cash Equivalents and Short-Term Investments | 22.55B | 31.13B | 21.18B | 19.22B | 27.35B |
| Total Debt | 1.72B | 1.97B | 832.30M | 1.13B | 1.52B |
| Total Liabilities | 17.28B | 16.84B | 14.95B | 13.67B | 14.04B |
| Stockholders Equity | 47.74B | 42.33B | 36.99B | 31.89B | 28.20B |
Cash Flow | |||||
| Free Cash Flow | 16.63B | 9.59B | 11.64B | 8.59B | 9.04B |
| Operating Cash Flow | 17.04B | 10.12B | 12.13B | 8.93B | 9.48B |
| Investing Cash Flow | -7.56B | 1.82B | -4.16B | -1.48B | -3.96B |
| Financing Cash Flow | -10.66B | -9.25B | -7.45B | -6.39B | -6.37B |
Abbott India Limited Technical Analysis
Negative
26135.85
Price Trends
26881.40
Negative
26314.31
Negative
26554.24
Negative
Market Momentum
-416.96
Positive
37.93
Neutral
17.42
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ABBOTINDIA, the sentiment is Negative. The current price of 26135.85 is above the 20-day moving average (MA) of 26089.73, below the 50-day MA of 26881.40, and below the 200-day MA of 26554.24, indicating a bearish trend. The MACD of -416.96 indicates Positive momentum. The RSI at 37.93 is Neutral, neither overbought nor oversold. The STOCH value of 17.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ABBOTINDIA.
Abbott India Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | ₹185.83B | 25.27 | ― | 1.85% | 10.69% | -9.09% | |
73 Outperform | ₹543.69B | 33.62 | ― | 2.05% | 6.29% | 11.18% | |
73 Outperform | ₹1.10T | 32.73 | ― | 2.12% | 1.85% | -37.51% | |
70 Outperform | ₹70.93B | 21.90 | ― | 4.00% | -8.88% | -10.68% | |
68 Neutral | ₹480.64B | 44.86 | ― | 2.01% | 5.75% | 12.41% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:ABBOTINDIA
Abbott India Limited
25,586.10
-4,633.55
-15.33%
IN:CIPLA
Cipla Ltd
1,365.00
-168.50
-10.99%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,837.20
150.40
5.60%
IN:PFIZER
PFIZER LIMITED
4,062.05
-1,019.41
-20.06%
IN:SANOFI
Sanofi India Limited
3,079.85
-1,812.36
-37.05%
IN:SANOFICONR
Sanofi Consumer Healthcare India Limited
4,039.05
-1,166.53
-22.41%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.